Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

354
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
354
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.7K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.7K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

331
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
331
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

102
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
102
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

744
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
744

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

D-Dimer levels during pregnancy and postpartum: non-applicability of regularly used cut-offs for diagnosis of suspected pulmonary embolism.

Archives of gynecology and obstetrics·2026
Same author

KRAS mutations in colorectal cancer patients receiving trifluridine/tipiracil plus bevacizumab: something to consider.

ESMO open·2025
Same author

Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?

ESMO open·2024
Same author

Sex-related differences of invasive therapy in patients with aneurysmal subarachnoid hemorrhage.

Acta neurochirurgica·2022
Same author

Active breaks: a strategy to counteract sedentary behaviors for Health Promoting Schools. A discussion on their implementation in Italy.

Annali di igiene : medicina preventiva e di comunita·2022
Same author

Effect of COVID-19 isolation measures on physical activity of children and their parents, and role of the family environment: a cross-sectional study.

Annali di igiene : medicina preventiva e di comunita·2022

Related Experiment Video

Updated: Dec 5, 2025

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.6K

Transfer Factor as an Option for Managing the COVID-19 Pandemic.

D Viza1, G Pizza2, C De Vinci2

  • 1Immunobiology Laboratory, Faculté de Médicine, Paris 6, France.

Folia Biologica
|October 18, 2020
PubMed
Summary

This study proposes testing transfer factor (TF), a safe immunomodulator, to combat COVID-19 (SARS-CoV-2). TF has a history of effectively treating and preventing viral infections, offering a potential therapeutic avenue.

More Related Videos

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.8K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K

Related Experiment Videos

Last Updated: Dec 5, 2025

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.6K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.8K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • COVID-19 (SARS-CoV-2) emerged in 2019, causing a global pandemic with significant mortality.
  • The virus is an RNA virus characterized by high infectivity and low mutability.
  • Limited treatment and vaccine availability necessitates exploring alternative therapeutic strategies.

Purpose of the Study:

  • To evaluate the potential of transfer factor (TF) as a treatment for COVID-19.
  • To explore TF's efficacy in preventing viral infections, drawing on past research.

Main Methods:

  • The study presents arguments for testing transfer factor (TF).
  • It highlights TF's established safety profile and lack of toxicity.
  • Past research on TF for viral infections is reviewed.

Main Results:

  • Transfer factor (TF) is an immunomodulator with a history of safe use.
  • TF has demonstrated efficacy in the treatment and prevention of various viral infections.

Conclusions:

  • Transfer factor (TF) is a promising candidate for further investigation against SARS-CoV-2.
  • Its immunomodulatory properties and safety profile warrant its consideration in managing the COVID-19 pandemic.